Share

November 2021; 8 (6) ArticleOpen Access

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis

Luca Prosperini, Serena Ruggieri, Shalom Haggiag, Carla Tortorella, Carlo Pozzilli, Claudio Gasperini
First published August 9, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001059
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1418

Share

Article Information

vol. 8 no. 6 e1059
DOI: 
https://doi.org/10.1212/NXI.0000000000001059
PubMed: 
34373345
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received May 24, 2021
  • Accepted in final form July 6, 2021
  • First Published August 9, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Luca Prosperini, MD, PhD,
    2. Serena Ruggieri, MD, PhD (serena.ruggieri{at}gmail.com),
    3. Shalom Haggiag, MD (lvshalom{at}hotmail.com),
    4. Carla Tortorella, MD (carla.tortorella{at}gmail.com),
    5. Carlo Pozzilli, MD, PhD (carlo.pozzilli{at}uniroma1.it) and
    6. Claudio Gasperini, MD, PhD (c.gasperini{at}libero.it)
  1. Luca Prosperini, MD, PhD,
    2. Scientific Advisory Boards:

    1. (1) Biogen (2) Celgene-BMS (3) Novartis (4) Sanofi Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Almirall (2) Biogen (3) Genzyme (4) Merck Serono (5) Novartis (6) Roche (7) Teva

    Editorial Boards:

    1. (1) BMC Neurology, associate editor, 2014 (2) BioMed Research International, associate editor, 2015

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Biogen (2) Novartis (3) Genzyme

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Genzyme, research grant

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Serena Ruggieri, MD, PhD (serena.ruggieri{at}gmail.com),
    3. Scientific Advisory Boards:

    1. (1) Merck Serono (2) Novartis (3) Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Merck Serono: speaker honoraria (2) Biogen: speaker honoraria (3) Merck Serono: Funding for travel (4) Biogen: Funding for travel

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Shalom Haggiag, MD (lvshalom{at}hotmail.com),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. travel funding and/or speaker honoraria from Roche, Genzyme, Novartis and CSL Behring

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Carla Tortorella, MD (carla.tortorella{at}gmail.com),
    5. Scientific Advisory Boards:

    1. Advisory board for Merck Serono, Teva, Genzyme, Biogen, Roche, Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. received honoraria for travel or speaking from Biogen, Sanofi-Aventis, Serono and Bayer-Schering, Teva, Genzyme, Roche and Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Carlo Pozzilli, MD, PhD (carlo.pozzilli{at}uniroma1.it) and
    6. Scientific Advisory Boards:

    1. Novartis, Merck Serono, Biogen, Sanofi-Aventis, Roche, Actelion

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Novartis, Merck Serono, Biogen,Sanofi Aventis, Roche.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Claudio Gasperini, MD, PhD (c.gasperini{at}libero.it)
    7. Scientific Advisory Boards:

    1. (1) Merck (2) Genzyme (3) Teva (4) Biogen (5) Roche (6) Almirall

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria for (1)Merck: speaker honoraria/ travel (2)Genzyme: speaker honoraria / travel (3)Biogen: speaker honoraria / travel (4)Teva: speaker honoraria / travel (5) Roche: speaker honoraria/travel (6)Novartis: travel

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurosciences (L.P., S.H., C.T., C.G.), S. Camillo-Forlanini Hospital; Department of Human Neurosciences (S.R., C.P.), Sapienza University; and Neuroimmunology Unit (S.R.), Santa Lucia Foundation, Rome, Italy.
  1. Correspondence
    Dr. Prosperini luca.prosperini{at}gmail.com

Article usage

Article usage: August 2021 to November 2023

AbstractFullPdfSource
Aug 202161837174Highwire
Sep 202123412108Highwire
Oct 20211621976Highwire
Nov 20216343102Highwire
Dec 2021913541Highwire
Jan 2022719947Highwire
Feb 20221926953Highwire
Mar 20222034584Highwire
Apr 20221722453Highwire
May 20221126698Highwire
Jun 20222028545Highwire
Jul 2022719741Highwire
Aug 2022823927Highwire
Sep 20221426232Highwire
Oct 20221028242Highwire
Nov 20222624248Highwire
Dec 20221224421Highwire
Jan 20231120729Highwire
Feb 20231715130Highwire
Mar 20231214637Highwire
Apr 2023810028Highwire
May 20231011338Highwire
Jun 20231411530Highwire
Jul 20231713032Highwire
Aug 202379827Highwire
Sep 2023149726Highwire
Oct 20231212621Highwire
Nov 2023137628Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles